Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The thickness of aortic valves was increased, and calcified regions were significantly elevated in dose-dependent manner following vitamin D treatment (p < 0.01, p < 0.0001, and p < 0.0001, respectively) (Figure 1B).

Source: 3.1. TNAP Is Overexpressed in CAVD. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Using a vitamin D3-induced CAVD mouse model presenting human-like annular thickening and valvular calcification, we analyzed the therapeutic impact of these inhibitors.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Inhibiting TNAP Attenuates the Aortic Valve Calcification and Reduces Oxidative Stress

Study design awaiting verification · Cells · 2026

Original publication title

Inhibiting TNAP Attenuates the Aortic Valve Calcification and Reduces Oxidative Stress

Hyeshin Kwon; Hak Su Kim; Minjeong Kwon; Soyoung Jo; Giwon Hwang; Sae-Kwang Ku; Ilwhea Ku; Yong Hwa Jo

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

Abstract: Highlights

What are the main findings?

  • Novel TNAP inhibition significantly attenuates aortic valve calcification by lowering elevated TNAP levels and reducing hydroxyapatite crystallization in a vitamin D3-induced CAVD mouse model.

  • TNAP inhibitors restore the valvular antioxidant defense system (GSH, SOD, CAT) while markedly suppressing lipid peroxidation (MDA, 4-HNE, MPO), pro-inflammatory cytokines (IL-1β, TNF-α), and apoptotic pathways (cleaved Cas-3, cleaved PARP).

What are the implications of the main findings?

  • Direct targeting of TNAP offers a viable, disease-modifying pharmacological strategy for advanced-stage CAVD, addressing the critical clinical gap where surgical or transcatheter valve replacement is currently the only option.

  • TNAP inhibition represents a promising therapeutic approach that successfully halts pathological cardiovascular remodeling (calcific, fibrotic, and osteogenic pathways) without compromising normal skeletal bone homeostasis in short-term models.

Source: Highlights Source: Highlights

Abstract: Abstract

Calcific aortic valve disease (CAVD) is a progressive condition driven by oxidative stress, chronic inflammation, and the osteogenic reprogramming of valvular interstitial cells, leading to hydroxyapatite crystallization. Because tissue non-specific alkaline phosphatase (TNAP) drives phosphate-mediated mineralization, this study evaluated the efficacy of novel TNAP inhibitors as a disease-modifying strategy. Using a vitamin D3-induced CAVD mouse model presenting human-like annular thickening and valvular calcification, we analyzed the therapeutic impact of these inhibitors. TNAP expression was highly elevated in diseased valves; however, inhibitor treatment significantly lowered TNAP levels and attenuated valvular calcification.

Notably, the inhibitors suppressed lipid peroxidation and restored antioxidant capacity, significantly regulating GSH, SOD, and CAT levels while decreasing lipid oxidation markers (MDA, 4-HNE, MPO). Furthermore, pro-inflammatory cytokines (IL-1β, TNF-α) and apoptotic markers (cleaved Cas-3, cleaved PARP) were markedly decreased, accompanied by diminished fibrotic and osteogenic remodeling, while maintaining normal bone homeostasis. In conclusion, TNAP inhibition effectively reduces pathological valve calcification by suppressing interconnected oxidative, inflammatory, fibrotic, and osteogenic pathways, positioning it as a promising and safe therapeutic approach for CAVD.

Source: Abstract
Authors’ abstract

Highlights

What are the main findings?

  • Novel TNAP inhibition significantly attenuates aortic valve calcification by lowering elevated TNAP levels and reducing hydroxyapatite crystallization in a vitamin D3-induced CAVD mouse model.

  • TNAP inhibitors restore the valvular antioxidant defense system (GSH, SOD, CAT) while markedly suppressing lipid peroxidation (MDA, 4-HNE, MPO), pro-inflammatory cytokines (IL-1β, TNF-α), and apoptotic pathways (cleaved Cas-3, cleaved PARP).

What are the implications of the main findings?

  • Direct targeting of TNAP offers a viable, disease-modifying pharmacological strategy for advanced-stage CAVD, addressing the critical clinical gap where surgical or transcatheter valve replacement is currently the only option.

  • TNAP inhibition represents a promising therapeutic approach that successfully halts pathological cardiovascular remodeling (calcific, fibrotic, and osteogenic pathways) without compromising normal skeletal bone homeostasis in short-term models.

Abstract

Calcific aortic valve disease (CAVD) is a progressive condition driven by oxidative stress, chronic inflammation, and the osteogenic reprogramming of valvular interstitial cells, leading to hydroxyapatite crystallization. Because tissue non-specific alkaline phosphatase (TNAP) drives phosphate-mediated mineralization, this study evaluated the efficacy of novel TNAP inhibitors as a disease-modifying strategy. Using a vitamin D3-induced CAVD mouse model presenting human-like annular thickening and valvular calcification, we analyzed the therapeutic impact of these inhibitors. TNAP expression was highly elevated in diseased valves; however, inhibitor treatment significantly lowered TNAP levels and attenuated valvular calcification.

Notably, the inhibitors suppressed lipid peroxidation and restored antioxidant capacity, significantly regulating GSH, SOD, and CAT levels while decreasing lipid oxidation markers (MDA, 4-HNE, MPO). Furthermore, pro-inflammatory cytokines (IL-1β, TNF-α) and apoptotic markers (cleaved Cas-3, cleaved PARP) were markedly decreased, accompanied by diminished fibrotic and osteogenic remodeling, while maintaining normal bone homeostasis. In conclusion, TNAP inhibition effectively reduces pathological valve calcification by suppressing interconnected oxidative, inflammatory, fibrotic, and osteogenic pathways, positioning it as a promising and safe therapeutic approach for CAVD.

Publication and source details

Original title: Inhibiting TNAP Attenuates the Aortic Valve Calcification and Reduces Oxidative Stress

Hyeshin Kwon; Hak Su Kim; Minjeong Kwon; Soyoung Jo; Giwon Hwang; Sae-Kwang Ku; Ilwhea Ku; Yong Hwa Jo

Cells · 2026

* Correspondence: joyh@rednvia.com
†

These authors contributed equally to this work.

© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.Korea Drug Development Fund funded by Ministry of Science and ICT, Ministry of Trade, Industry, and Energy, and Ministry of Health and WelfareRS-2023-00217370This research was supported by Korea Drug Development Fund funded by Ministry of Science and ICT, Ministry of Trade, Industry, and Energy, and Ministry of Health and Welfare (RS-2023-00217370, Republic of Korea).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:49:18.987112+00:00

DOI: 10.3390/cells15171543 · PMC13564631